Aura Biosciences Inc

AURA remains in a confirmed Stage 4 decline with a negative EMA regime and persistent lower highs/lows. Medium‐term bias is bearish, but price is now oversold and extended below key EMAs. We defer selling until relief rallies into the 9/21 EMA & 50 SMA zone for rejection‐based trimming.

• ↑Strategic pivot to ocular oncology with Phase 3 CoMpass enrollment of 108 patients
• ↑Cash and equivalents of $323.8 M fund operations into H1 2029
• ↓Q2 2026 net loss widened to $45.6 M from $27 M YoY